PMID- 21072898
OWN - NLM
STAT- MEDLINE
DCOM- 20110228
LR  - 20220409
IS  - 2219-2840 (Electronic)
IS  - 1007-9327 (Print)
IS  - 1007-9327 (Linking)
VI  - 16
IP  - 42
DP  - 2010 Nov 14
TI  - Comparative study of therapeutic effects of PPI and H2RA on ulcers during 
      continuous aspirin therapy.
PG  - 5342-6
AB  - AIM: To compare the therapeutic effects of proton pump inhibitors (PPI) and 
      histamine 2 receptor antagonists (H2RA) on gastroduodenal ulcers under continuous 
      use of low-dose aspirin. METHODS: Sixty patients who had a gastroduodenal ulcer 
      on screening endoscopy but required continuous use of low-dose aspirin were 
      randomly assigned to receive PPI (lansoprazole 30 mg, n = 30) or H2RA (famotidine 
      40 mg or if famotidine had been administered before assignment, ranitidine 300 
      mg, n = 30). The therapeutic effects were evaluated by endoscopy after 8-wk 
      treatment. The presence or absence of Helicobacter pylori (H. pylori) was 
      determined by urea breath test before treatment. Abdominal symptoms were compared 
      with the gastrointestinal symptom rating scale (GSRS) questionnaire before and 
      after treatment. RESULTS: Twenty-six patients in the PPI group and 26 patients in 
      the H2RA group, excluding dropouts, were analyzed. There were no significant 
      differences in median age, sex, underlying disease, smoking status, H. pylori 
      infection, prevalence of ulcers before treatment, and lesion site between the two 
      groups. The therapeutic effects were endoscopically evaluated as healed in 23 
      patients (88.5%) and not healed in 3 patients in the PPI group and as healed in 
      22 patients (84.6%) and not healed in 4 patients in the H2RA group. Abdominal 
      symptoms before treatment were uncommon in both groups; the GSRS scores were not 
      significantly reduced after treatment as compared with before treatment. 
      CONCLUSION: The healing rate of gastroduodenal ulcers during continuous use of 
      low-dose aspirin was greater than 80% in both the PPI group and the H2RA group, 
      with no significant difference between the two groups.
FAU - Nema, Hiroaki
AU  - Nema H
AD  - Department of Internal Medicine, Teishinkai Hospital, North 44, East 8, 
      Higashi-ku, Sapporo, Hokkaido 007-0844, Japan.
FAU - Kato, Mototsugu
AU  - Kato M
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - United States
TA  - World J Gastroenterol
JT  - World journal of gastroenterology
JID - 100883448
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Inflammatory Agents, Non-Steroidal)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Histamine H2 Antagonists)
RN  - 0 (Proton Pump Inhibitors)
RN  - 0K5C5T2QPG (Lansoprazole)
RN  - 5QZO15J2Z8 (Famotidine)
RN  - 884KT10YB7 (Ranitidine)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/therapeutic use
MH  - Aged
MH  - Anti-Inflammatory Agents, Non-Steroidal/*therapeutic use
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aspirin/*therapeutic use
MH  - Drug Therapy, Combination
MH  - Endoscopy
MH  - Famotidine/therapeutic use
MH  - Histamine H2 Antagonists/*therapeutic use
MH  - Humans
MH  - Lansoprazole
MH  - Male
MH  - Middle Aged
MH  - Peptic Ulcer/*drug therapy
MH  - Prospective Studies
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Ranitidine/therapeutic use
MH  - Treatment Outcome
MH  - Wound Healing
PMC - PMC2980684
EDAT- 2010/11/13 06:00
MHDA- 2011/03/01 06:00
PMCR- 2010/11/14
CRDT- 2010/11/13 06:00
PHST- 2010/11/13 06:00 [entrez]
PHST- 2010/11/13 06:00 [pubmed]
PHST- 2011/03/01 06:00 [medline]
PHST- 2010/11/14 00:00 [pmc-release]
AID - 10.3748/wjg.v16.i42.5342 [doi]
PST - ppublish
SO  - World J Gastroenterol. 2010 Nov 14;16(42):5342-6. doi: 10.3748/wjg.v16.i42.5342.